<DOC>
	<DOCNO>NCT01888120</DOCNO>
	<brief_summary>The objective study evaluate effectiveness , long-term safety , tolerability , satisfaction treatment , health-related quality life ( HRQoL ) associate Intrathecal PRIALT use severe chronic pain vary etiology .</brief_summary>
	<brief_title>Patient Registry Intrathecal Ziconotide Management ( PRIZM )</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Ziconotide</mesh_term>
	<mesh_term>omega-Conotoxins</mesh_term>
	<criteria>Patient least 18 year age time study entry . Patient severe chronic pain , IT therapy warrant , intolerant , refractory treatment , systemic analgesic , adjunctive therapy , and/or IT morphine . Patient plan initiate IT PRIALT sole agent pump participate site . Patient receive PRIALT treatment administer continuously via Medtronic SynchroMedÂ® II pump within past 30 day . Patient life expectancy &gt; 6 month determine physician . Patient able read , understand , voluntarily sign IRBapproved inform consent document prior performance studyspecific procedure . Patient able understand complete require assessment . Patient known hypersensitivity PRIALT formulation component . Patient preexist history psychosis . Patient infection microinjection site , uncontrolled bleeding diathesis , know spinal canal obstruction impairs circulation cerebrospinal fluid . Patient initiate PRIALT conjunction IT agents . Patients concomitant treatment medical condition , opinion clinician , would render IT administration hazardous .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>